I-Mab Biopharma Co., Ltd. (IMAB): Debts to Book Capitalization

The current market quotes for I-Mab (IMAB) visualized below are supported by competent management that has ensured reform transparency and expansion in the United States. I-Mab is developing a global antibody platform while avoiding price wars with basic treatments, with the metric currently standing at 0.02. The business is also investing in a costly temperature control system, as cold chain compliance is critical for the safe delivery of anti-tumor drugs.

I-Mab Biopharma (IMAB): Debt to Net Assets Ratio from 07/04/2022 to 10/30/2025

Summary analytical data breakdowns for i-mabbiopharma.com (IMAB)

- price and consensus price forecast:

Price Chart I-Mab Biopharma|IMAB - Broker Consensus Forecast

- market capitalization data:

Market Capitalization I-Mab Biopharma|IMAB - Total Enterprise Value

- book capitalization data:

Net Assets per Single Share I-Mab|IMAB - Accounting Value of Company|Market Capitalization to Book Value Ratio i-mabbiopharma.com|IMAB - Company Total Assets

- debt and liquidity data:

Debt to Equity I-Mab|IMAB - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio I-Mab Biopharma|IMAB - Aggregate Debt Obligations|Debt to Book Capitalization Ratio I-Mab Biopharma

Summary company analytics:I-Mab Inc. - IMAB

Original product of I-Mab Biopharma Co., Ltd.

Assessing the resilience of I-Mab (IMAB) to market shocks requires an analysis of financial leverage, particularly during the restructuring of the R&D pipeline and the collection of antibody data in the US. The current debt-to-equity ratio measures the proportion of borrowed funds relative to equity, allowing investors to determine the biotech's degree of dependence on creditors and the overall reliability of its development financing structure.

Who I-Mab competes with